Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California and currently employs 50 full-time employees. The company went IPO on 2014-02-05. The firm has developed a patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, it is a commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample. The firm operates a clinical laboratory and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. The assays the Company offers are classified as laboratory developed tests (LDT) under the CLIA regulations. The Company’s assays, performed on cerebral spinal fluid, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease.
Follow-Up Questions
Quel est le ratio P/E de Biocept Inc (BIOCQ) ?
Le ratio P/E de Biocept Inc est de 0
Quelle est la performance du prix de l'action BIOCQ ?
Le prix actuel de BIOCQ est de $0.0001, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Biocept Inc ?
Biocept Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Biocept Inc ?
La capitalisation boursière actuelle de Biocept Inc est de $263
